Bio

Bio


Dr. MyMy Buu is a board certified pediatric pulmonologist and specializes in the treatment of pediatric lung diseases including: respiratory complications of neuromuscular disease, pulmonary sequela of aspiration, chronic lung disease of prematurity, asthma, cystic fibrosis, chronic respiratory failure. She has practiced pediatrics and pediatric pulmonary for more than 10 years.

Dr. Buu is dedicated to caring for children with chronic disease and special health care needs. She is one of the pulmonologists for a number of multidisciplinary care teams including the Pediatric Cystic Fibrosis Center, Aerodigestive Program, and Neuromuscular Disorders Program.

Her scholarly work has been focused on pediatric health in vulnerable communities. Her current research is in clinical epidemiology in patients with cystic fibrosis. The aims are to identify disparities in health outcomes and to describe opportunities for improvement so that all patients can have healthier longer lives.

In her free time, she likes spend time with her young children, cook, and travel.

Clinical Focus


  • Cystic Fibrosis
  • Aerodigestive Disorders
  • Neuromuscular Disease
  • Chronic Respiratory Failure / Mechanical Ventilation
  • Bronchopulmonary Dysplasia
  • Diffuse Lung Disease / Interstitial Lung Disease
  • Pediatric Pulmonary

Academic Appointments


Administrative Appointments


  • Associate Program Director, Stanford University School of Medicine, Pediatric Pulmonary Fellowship (2016 - Present)
  • Pediatric Residency Pulmonary Rotation Director, Stanford University School of Medicine, Pediatric Residency (2013 - Present)

Honors & Awards


  • Community Access to Child Health Grant, American Academy of Pediatrics (December 2007-June 2009)
  • 2nd year Clinical Fellowship, Cystic Fibrosis Foundation (July 2010-June 2011)
  • Crandall Endowed Fellowship, Stanford University School of Medicine (July 2010-June 2011)
  • Ernest and Amelia Gallo Endowed Fellow, Lucile Packard Foundation for Children's Health (July 2011-June 2012)
  • Scholar, Bass Society of Pediatric Scholars (June 2012)

Boards, Advisory Committees, Professional Organizations


  • Member, Program Committee, American Thoracic Society (2016 - Present)
  • Member, American Thoracic Society (2009 - Present)
  • Fellow, American Academy of Pediatrics (2004 - Present)

Professional Education


  • Medical Education:UCLA General Surgery Residency (2006) CA
  • Board Certification: Pediatric Pulmonary, American Board of Pediatrics (2012)
  • Fellowship:Stanford Hospital and Clinics (2012) CA
  • Board Certification: Pediatrics, American Board of Pediatrics (2009)
  • Residency:Stanford Hospital and Clinics (2009) CA
  • Internship:Stanford Hospital and Clinics (2007) CA

Research & Scholarship

Current Research and Scholarly Interests


My current research investigates the determinants of health for Hispanic patients with cystic fibrosis. Specifically, I am interested in identifying modifiable causes of health inequalities.
I have had a range of mentored research experiences during my educational and medical training, ranging in developmental biology to community-based participatory research. My prior work included conducting a community needs assessment for caregivers of Vietnamese-American children in San Jose, CA. My research has involved using large administrative databases to explore healthcare utilization patterns in Hispanic patients with cystic fibrosis.

Teaching

Graduate and Fellowship Programs


  • Pediatric Pulmonology (Fellowship Program)

Publications

All Publications


  • Tear Down this Wall: Diversity and Disparities in Cystic fibrosis. American journal of respiratory and critical care medicine Buu, M. C., Milla, C. E. 2018

    View details for DOI 10.1164/rccm.201806-1076ED

    View details for PubMedID 30063377

  • Respiratory complications, management and treatments for neuromuscular disease in children CURRENT OPINION IN PEDIATRICS Buu, M. C. 2017; 29 (3): 326-333

    Abstract

    To summarize current literature describing the respiratory complications of neuromuscular disease (NMD) and the effect of respiratory interventions and to explore new gene therapies for patients with NMD.Measurements of respiratory function focus on vital capacity and maximal inspiratory and expiratory pressure and show decline over time. Management of respiratory complications includes lung volume recruitment, mechanical insufflation-exsufflation, chest physiotherapy and assisted ventilation. Lung volume recruitment can slow the progression of lung restriction. New gene-specific therapies for Duchenne muscular dystrophy and spinal muscular atrophy have the potential to preserve respiratory function longitudinally. However, the long-term therapeutic benefit remains unknown.Although NMDs are heterogeneous, many lead to progressive muscle weakness that compromises the function of the respiratory system including upper airway tone, cough and secretion clearance and chest wall support. Respiratory therapies augment or support the normal function of these components of the respiratory system. From a respiratory perspective, the new mutation and gene-specific therapies for NMD are likely to confer long-term therapeutic benefit. More sensitive and standard tools to assess respiratory function longitudinally are needed to monitor respiratory complications in children with NMD, particularly the youngest patients.

    View details for DOI 10.1097/MOP.0000000000000498

    View details for Web of Science ID 000401074000012

    View details for PubMedID 28338488

  • Developing Gene-Specific Meta-Predictor of Variant Pathogenicity bioRxiv Rychkova, A., Buu, M., Scharfe, C., Lefterova, M., Odegaard, J., Schrijver, I., Milla, C., Bustamante, C. 2017

    View details for DOI 10.1101/115956

  • Ocular manifestations of pulmonary diseases The Eye in Pediatric Systemic Disease Yoo, S., Buu, M. Springer International Publishing. 2017
  • Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California CHEST Buu, M. C., Sanders, L. M., Mayo, J. A., Milla, C. E., Wise, P. H. 2016; 149 (2): 380-389

    Abstract

    Over the past 30 years, therapeutic advances have extended the median life span of patients with cystic fibrosis (CF). Hispanic patients are a vulnerable subpopulation with high of prevalence of risk factors for worse health outcomes. The consequences of these differences on health outcomes have not been well described. The objective of this study is to characterize the difference in health outcomes, including mortality rate, between Hispanic and non-Hispanic patients with CF.Retrospective analysis of CF Foundation patient registry data of California residents with CF, diagnosed during or after 1991, from 1991-2010. Ethnicity was self-reported. Primary outcome was mortality. Hazard ratios were estimated from a Cox regression model, stratified by gender and adjusted for socioeconomic status, clinical risk factors, and year of diagnosis.Of 1719, 485 (28.2%) self-identified as Hispanic. Eighty-five deaths occurred, with an overall mortality rate of 4.9%. Unadjusted mortality rate was higher among Hispanic patients than non-Hispanic patients (9.1% vs. 3.3%, p<0.0001). Compared with non-Hispanic patients, Hispanic patients had lower survival rate 18 years post-diagnosis (75.9% vs. 91.5%, p<0.0001). Adjusted for socioeconomic status and clinical risk factors, Hispanic patients had increased rate of death compared to non-Hispanic patients (HR 2.81, 95% CI 1.70-4.63).Hispanic patients with CF have a higher mortality rate than non-Hispanic patients, even after adjusting for socioeconomic status and clinical severity. Further investigation of mechanism for the measured difference in lung function will help inform interventions and improve the health of all CF patients.

    View details for DOI 10.1378/chest.14-2189

    View details for Web of Science ID 000369660400021

  • Asthma, tobacco smoke and the indoor environment: a qualitative study of sheltered homeless families JOURNAL OF ASTHMA Buu, M. C., Carter, L., Bruce, J. S., Baca, E. A., Greenberg, B., Chamberlain, L. J. 2014; 51 (2): 142-148

    Abstract

    Asthma is common in homeless children with an incidence of 28-40%. There are few published studies investigating asthma in homeless children. This study examines the perspectives of both caregivers and shelter staff regarding challenges and opportunities of caring for children with asthma.A focus group of sheltered parents (n = 10) with children who have asthma was conducted to identify barriers to optimal asthma management. Key informant interviews (n = 6) were conducted with shelter staff to discuss the shelter systems and policies to address childhood asthma. Data were audio-recorded and transcribed. A representative analysis team performed qualitative theme analysis.Key themes across 5 domains were identified: asthma education, access to asthma medication and equipment, asthma action plans, structural barriers to asthma management and environmental triggers. Parents identified multiple asthma triggers present in the shelter environment but cited lack of control as a barrier to remediation. Shelter staff desired elimination of asthma triggers but refer to the lack of resources as the primary barrier. Shelter staff favored a smoking ban on shelter property but named challenges to policy implementation. Both parents and staff identified asthma education and increased access to medications would be helpful.Policies to reduce environmental exposures, such as a smoking ban, to asthma triggers has the potential to improve the health of sheltered children with asthma.

    View details for DOI 10.3109/02770903.2013.857682

    View details for Web of Science ID 000331908900005

    View details for PubMedID 24147583